Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
Phase 1 Completed
50 enrolled
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
Phase 1 Completed
14 enrolled
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma
Phase 1 Completed
20 enrolled
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Phase 1 Completed
5 enrolled
CAR-37 T Cells in Hematologic Malignancies
Phase 1 Completed
6 enrolled
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Phase 1 Completed
91 enrolled
Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Phase 1 Completed
14 enrolled
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Phase 1 Completed
8 enrolled 18 charts
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Phase 1 Completed
15 enrolled 18 charts
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
Phase 1 Completed
44 enrolled
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Phase 1 Completed
12 enrolled 4 charts
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1 Completed
24 enrolled
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1 Completed
55 enrolled
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
Phase 1 Completed
26 enrolled
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
Phase 1 Completed
22 enrolled
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Phase 1 Completed
17 enrolled
Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1 Completed
2 enrolled
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
Phase 1 Completed
39 enrolled
AMG 319 Lymphoid Malignancy FIH
Phase 1 Completed
28 enrolled
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
Phase 1 Completed
48 enrolled
PI3K
Phase 1 Completed
35 enrolled
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Phase 1 Completed
13 enrolled
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
121 enrolled
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Phase 1 Completed
80 enrolled
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Phase 1 Completed
8 enrolled
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
Phase 1 Completed